Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Marcus E Carr"'
Autor:
Katherine A. High, Mary Robinson, Marcus E. Carr, Stefan Tiefenbacher, Benjamin J. Samelson-Jones, Valder R. Arruda, John E. Murphy, Denis Rybin, Lindsey A. George, Jeremy Rupon
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Limited information exists regarding the factor IX (FIX) coagulant activity (FIX:C) measured by different assays following FIX‐Padua gene therapy. Objective Assess for the first time FIX:C in five commonly used coagulation assays in plas
Autor:
Pablo Rendo, Kaan Kavakli, Marcus E. Carr, Lynne Smith, Bartholomew J Tortella, Joan M. Korth-Bradley
In a pivotal, multicenter, open-label study, 25 patients aged 12-54 years with moderately severe/severe hemophilia B received on-demand nonacog alfa (6 months; dose at investigator's discretion) followed by once-weekly prophylaxis with nonacog alfa 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae56f98e0083b772a756c01a839becc8
https://hdl.handle.net/11454/77394
https://hdl.handle.net/11454/77394
Autor:
Johannes C.M. Van der Loo, Jerome M. Teitel, Benjamin J. Samelson-Jones, Adam Cuker, Xavier M. Anguela, Marcus E. Carr, Catherine E. McGuinn, Yifeng Chen, Linda B. Couto, Adam Giermasz, Suvankar Majumdar, Katie Wachtel, Jonathan M. Ducore, Stefan Tiefenbacher, Margaret V. Ragni, J. Fraser Wright, Olga Zelenaia, Katherine A. High, Yun Liu, John E.J. Rasko, Daniel Takefman, Lisa M. Sullivan, Angela Winters, Daniel Hui, Alvin Luk, Spencer K. Sullivan, Valder R. Arruda, Lindsey A. George
Publikováno v:
The New England journal of medicine. 377(23)
The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia.We infused a si
Publikováno v:
Haemophilia
Spontaneous haemorrhage in patients with haemophilia is generally considered to occur randomly and without a predictable temporal or seasonal pattern; however, there is a lack of evidence in the literature on the effects of weather, temperature and a
Autor:
Xavier M. Anguela, Katie Wachtel, Judith Kadosh, Stacy E. Croteau, Marcus E. Carr, Lindsey A. George, Leonard A. Valentino, Matthew S. Evans, Federico Mingozzi, Linda B. Couto, Daniel Takefman, Kathleen B Reape, Daniel J. Hui, Alexa R. Runoski, Amy Macdougall, Katherine A. High, Cynthia Campbell-Baird, Marcelyne Joseney-Antoine, Ben J. Samelson-Jones, Howard Hait, Summer Tompkins, Spencer K. Sullivan, Ashlyn Eaton Bassiri, M. Elaine Eyster, Kayla Douglas, Margaret V. Ragni
Publikováno v:
Blood. 132:487-487
Gene transfer for hemophilia A offers the potential for a one-time disease altering treatment, eliminating the risk of bleeds while freeing patients from the burden of lifelong chronic therapy. SPK-8011 consists of a bioengineered AAV capsid expressi
Autor:
Katherine A. High, Valder R. Arruda, Lindsey A. George, Benjamin J. Samelson-Jones, Mary Robinson, Marcus E. Carr, Stefan Tiefenbacher
Publikováno v:
Blood. 132:2198-2198
Background PF-06838435 (SPK-9001), a gene therapy candidate containing a high specific-activity factor IX variant (R338L, FIX-Padua), is currently in phase 3 of clinical development for the treatment of Hemophilia B. Initial data with this vector is
Publikováno v:
Encyclopedia of Biomedical Polymers and Polymeric Biomaterials ISBN: 1439898790
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abbc403aba0bfa21ff455627d237d509
https://doi.org/10.1081/e-ebpp-120007296
https://doi.org/10.1081/e-ebpp-120007296
Publikováno v:
Journal of Thrombosis and Haemostasis. 4:372-376
Summary. Background: Patients with end-stage renal disease (ESRD) who receive enoxaparin are at increased risk for adverse bleeding episodes. This phenomenon appears to occur despite judicious monitoring of antifactor Xa (aFXa) activity. Better monit
Autor:
James French, Gilbert C. White, Joan Cox Gill, Felicia Kiplinger, Richard Lipton, James J. Goedert, Melinda E Nolte, Charles Cooper, Brittan Browning, Kathryn Galli, Nigel S. Key, Anastasia Karafoulidou, Craig M. Kessler, Christine Guelcher, Michael W. Fried, Howard A. Britton, Amy D. Shapiro, Catherine S. Manno, Naomi L.C. Luban, Aime L. Grimsley, Cindy A. Leissinger, Johanna McCarthy, John J. Hutter, Alexis A. Thompson, Dorine Belliveau, Michael Lammer, Anne L. Angiolillo, Keith Hoots, Zale P. Bernstein, Willis H. Navarro, Anastasia E. Lee, Jeanne M. Lusher, Ilene Goldberg, Muriel Herr, Linda Percy, Gina Stack, Kevin McRedmond, Kay Miller, Amanda Wade, Christine Pece, Richard S. Lemons, Sandra Hibner, Deborah L Brown, Jodie Nelson, Cecilia V. Schmidt, Charles Sexauer, Anita Smith, Prasad Matthew, Barbara A. Konkle, Kenneth E. Sherman, Sheldon H. Rubin, Hernan Sabio, Vicky Hannemann, M. Ullman, Judy A. Bagato, Donna DiMichele, Jerry S. Powell, Regina Butler, Marilyn J. Manco-Johnson, Patti Noblet, Lori Laudenbach, Kathi Cobb, Madeline Heffner, Arthur R. Thompson, Marcus E. Carr, Ralph A. Gruppo, Sheryl Giambartolomei, Suzi Greer, J. E. Palascak, Donald Lilley, Jaime Siegel, Louis M. Aledort, Michael M. Lederman, Marge Halley, Nirmala Vijayanathan, Linda Belling, Jessie Roth, Steven Klintworth, Shirley Bleak, Diane J. Nugent, Michael D. Tarantino, Jorge DiPaolo, Lawrence Jardine, Rathi V. Iyer, Mary Lou Damiano, Karen Scott, Anne T. Neff, Steven Faust, Susan Gamerman, Hans Joachim Reimers, Eric H. Kraut, Marcia Schwartz, M. Elaine Eyster, Gillian Jenkins, Marianne McDaniel, Leslie Witkoff, James P. Steinberg, Marion Dugdale, Janice S. Withycombe
Publikováno v:
Haemophilia. 11:516-528
Before the mid-1980s, haemophilia often was unknowingly treated with contaminated plasma products, resulting in high rates of human immunodeficiency virus (HIV-1), hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. To estimate the impact
Autor:
Brian Vickaryous, Marcus E. Carr
Publikováno v:
Blood Coagulation & Fibrinolysis. 24:436-438
Due to the lack of adequate controlled trials, the off-label use of recombinant factor VIIa (rFVIIa) to control hemorrhage in trauma patients remains controversial. The decision regarding when to initiate rFVIIa therapy is particularly problematic. W